Metzger Michael A's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Feb 8, 2023
- Accession no.
- 0001562180-23-001118
- Filed
- Feb 8, 2023
- Trade date
- Feb 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $164.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Metzger Michael ACIK 0001507220 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Common Stock | MOption exerciseAcquired | +5,959 | $6.38 | +$38,018.42 | 23,618 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −5,959 | $27.64 | −$164,706.76 | 17,659 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Common Stock | MOption exerciseDisposed | −5,959 | $27.64 | −$164,706.76 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.